Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial - CaVenT

Eastern Norway Regional Health Authority0 个研究点目标入组 200 人开始时间: 2005年11月4日最近更新: 2015年12月22日

适应症

试验速览

暂无简介。

•1 Age 18-75 years.
•2 Onset of symptoms <21 days.
•3 Objectively (ultrasonography, venography, computer tomography, or magnetic resonance imaging) verified DVT of the femoral or common iliac veins or the combined iliofemoral segment.
•4 Informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1 Anticoagulant therapy prior to trial entry for >7 days.
•2 Contraindications to thrombolytic therapy, including bleeding diathesis.
•3 Indications for thrombolytic therapy, e.g., phlegmacia coerolia dolens or vena cava thrombosis.
•4 Severe anemia (hemoglobin <8 g/dL).
•5 Thrombocytopenia (platelets <80•109/L).
•6 Severe renal failure – creatinine clearance <30 ml/min.
•7 Severe hypertension, i.e. persistent systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg.
•8 Pregnancy (but post-partum thrombosis may be included).
•9 Less than 14 days post-surgery or post-trauma.
•10 History of subarachnoidal or intracerebral bleeding.
•11 Disease with life expectancy < 24 months.
•12 Drug abuse or mental disease that may interfere with treatment and follow-up.
•13 Former ipsilateral proximal DVT.
•14 Chemotherapy/advanced malignant disease.

发起方

Eastern Norway Regional Health Authority